Dehaier profits are 70 percent higher | Earnings roundup

MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.

Here’s a quick rundown of a few releases over the past couple days:

Dehaier profits are 70 percent higher
Dehaier Medical Systems Ltd. (NSDQ:DHRM) reported profits of $1.5 million or 32 cents per diluted share, on sales of $6.7 million during the three months ended Dec. 31. That compares with profits of $621,641, or 20 cents per diluted share, on sales of $2.9 million during the same period last year.

Full-year profits were $4.6 million, or $1.09 per diluted share, on sales of $19.6 million. That compares with profits of $2.7 million, or 89 cents per diluted share, on sales of $12.4 million in 2009.
Read more

Neoprobe 2010 losses widen more than 25 percent, but sales get 13 percent bump
Neoprobe Corp. (NYSE Amex:NEOP) reported losses of $2.1 million, or 3 cents per diluted share, on sales of $3.2 million during the three months ended Dec. 31. That compares with a losses of $293,638, or less than 1 cents per diluted share, on sales of $2.4 million during the same period in 2009.

Full-year losses were $50.0 million, or 72 cents per diluted share, on sales of $10.7 million. That compares with losses of $39.8 million, or 54 cents per diluted share, on sales of $9.5 million in 2009.
Read more

Elekta on the rise
Elekta AB (STO:EKTA-B) reported net income of $30.1 million on sales of $280.8 million during the three months ended Jan. 31, 2011. That compares with net income of $22.7 million on sales of $262.3 million during the same period in 2009.
Read more

RBC sales, profits see increases
RBC Life Sciences Inc. (OTC:RBCL) reported profits of $558,000, or 2 cents per diluted share, on sales of $28.2 million in the year ended Dec. 31, 2010. That compares with a loss of $335,000, or 2 cents per diluted share, on sales of $24.9 million for 2009.
Read more

Cerus cuts losses after increased sales
Cerus Corp. (NSDQ:CERS) reported losses of $2.6 million or 6 cents per diluted share, on sales of $6.0 million during the three months ended Dec. 31. That compares with losses of $4.9 million, or 13 cents per diluted share, on sales of $5.2 million during the same period last year.

Full-year losses were $16.9 million, or 42 cents per diluted share, on sales of $21.7 million. That compares with losses of $24.1 million, or 69 cents per diluted share, on sales of $16.8 million in 2009.
Read more

DexCom sales more than double, but losses worsen
DexCom Inc. (NSDQ:DXCM) reported losses of $9.8 million, or 16 cents per diluted share, on sales of $13.6 million during the three months ended Dec. 31. That compares with losses of $11.5 million, or 25 cents per diluted share, on sales of $6.6 million during the same period last year.

Full-year losses were $55.2 million, or 97 cents per diluted share, on sales of $40.2 million. That compares with losses of $53.5 million, or $1.21 per diluted share, on sales of $18.0 million in 2009.
Read more

American Shared Hospital Services reports stagnant sales
American Shared Hospital Services (NYSE Amex:AMS) reported profits of $40,000, or 1 cent per diluted share, on sales of $4.2 million during the three months ended Dec. 31. That compares with a loss of $137,000 or 3 cents per diluted share, on sales of $4.1 million during the same period last year.

Full-year profits were $57,000, or 1 cent per diluted share, on sales of $16.7 million. That compares with a loss of $188,000, or 4 cents per diluted share, on sales of $16.8 million in 2009.
Read more

GenMark losses ease after sales rocket more than 150 percent
GenMark Diagnostics Inc. (NSDQ:GNMK) reported losses of $3.5 million, or 30 cents per diluted share, on sales of $787,482 during the three months ended Dec. 31, 2010. That compares with losses of $5.6 million, or $1.07 per diluted share, on sales of $302,410 during the same period in 2009.

Full-year losses were $18.4 million, or $1.88 per diluted share, on sales of $2.5 million. That compares with losses of $20.0 million, or $4.41 per diluted share, on sales of $998,416 in 2009.
Read more

IRIDEX profits get 15 percent bump on modest sales increase
IRIDEX Corp. (NSDQ:IRIX) reported profits of $837,000, or 8 cents per diluted share, on sales of $12.2 million during the three months ended Jan. 1, 2011. That compares with profits of $517,000, or 5 cents per diluted share, on sales of $11.6 million during the same period in 2009.

Full-year profits were $3.0 million, or 30 cents per diluted share, on sales of $43.7 million. That compares with profits of $2.6 million, or 26 cents per diluted share, on sales of $43.2 million in 2009.
Read more

Safeguard Scientifics’ Q4 beats year
Safeguard Scientifics Inc. (NYSE:SFE) reported profits of $45.4 million, or $1.84 per diluted share, on revenue of $0 during the three months ended Dec. 31, 2010. That compares with losses of $58.0 million, or $2.85 per diluted share, on revenue of $0 during the same period in 2009.

Full-year profits were $27.1 million, or $1.26 cents per diluted share, on revenue of $0. That compares with profits of $68.8 million, or $3.14 per diluted share, on revenue of $34.8 million in 2009.
Read more